Oncology | Phase III Developments | FRANCE

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sarclisa Combination Therapy Demonstrated Superior Progression Free Survival and Clinically Meaningful Depth of Response In Relapsed Multipl...

Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sanofi's Sarclisa Cuts Death Risk In Mutiple Myeloma

Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone alone.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sanofi, Regeneron Tout Libtayo's First Lung Cancer Win

Lead Product(s): Cemiplimab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Protocol-specified interim analysis conducted by the Independent Data Monitoring Committee demonstrated that patients treated with Libtayo monotherapy had a significant increase in overall survival.

Ipsen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib + Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Prostate Cancer

Lead Product(s): Cabozantinib,Atezolizumab

Therapeutic Area: Oncology Product Name: Cabometyx

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Exelixis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 02, 2020

Details:

Ipsen will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials.

Ipsen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ipsen Presents Phase I/II Data Testing Onivyde as an Investigational First-Line Combination Treatment for Metastatic Pancreatic Cancer

Lead Product(s): Irinotecan,Oxaliplatin,Leucovorin Calcium

Therapeutic Area: Oncology Product Name: Onivyde

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

Ipsen has initiated the NAPOLI-3 Phase III clinical study (NCT04083235) comparing the safety and efficacy of liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) (NALIRIFOX) to gemcitabine + nab-paclitaxel in the first-line setting.

Ipsen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ipsen Receives FDA Fast Track Designation for ONIVYDE as a First-Line Combination Treatment for Metastatic Pancreatic Cancer

Lead Product(s): Irinotecan,Oxaliplatin,Leucovorin Calcium

Therapeutic Area: Oncology Product Name: Onivyde

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

US FDA has granted the company Fast Track designation for the investigational use of ONIVYDE in combination with 5- fluorouracil/leucovorin & oxaliplatin, for patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma.

OSE Immunotherapeutics SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Phase 3 Clinical Trial of Tedopi OSE Immunotherapeutics Announces Positive Top-Line Results

Lead Product(s): OSE2101

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Primary endpoint was met in the predefined Step-1 analysis of its Phase 3 clinical trial of investigational product Tedopi®, called Atalante 1, in HLA-A2 positive non-small cell lung cancer.

Ipsen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

Lead Product(s): Fluorouracil,Leucovorin Calcium,Irinotecan

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

Ipsen will continue the development of palovarotene, conduct further assessment of the MOVE dataset,

AB Science SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer...

Lead Product(s): Masitinib,Docetaxel,Prednisone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

Study AB12003 is a multicenter, randomized, double blind, placebo-controlled, 2-parallel group, Phase 3 study in metastatic castrate resistant prostate cancer eligible to chemotherapy.

Nanobiotix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update

Lead Product(s): Hafnium dioxide,Cisplatin,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

NANOBIOTIX will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology program.

Find

Find Oncology Drugs in Phase III Clinical Development in FRANCE

France

Product Type

Companies

Sanofi

Sarclisa Combination Therapy Demonstrated Superior Progression Free Survival and Clinically Meaningful Depth of Response In Relapsed Multipl...

Sanofi

Sanofi's Sarclisa Cuts Death Risk In Mutiple Myeloma

Sanofi

Sanofi, Regeneron Tout Libtayo's First Lung Cancer Win

Ipsen

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib + Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Prostate Cancer

Ipsen

Ipsen Presents Phase I/II Data Testing Onivyde as an Investigational First-Line Combination Treatment for Metastatic Pancreatic Cancer

Ipsen

Ipsen Receives FDA Fast Track Designation for ONIVYDE as a First-Line Combination Treatment for Metastatic Pancreatic Cancer

OSE Immunotherapeutics SA

Phase 3 Clinical Trial of Tedopi OSE Immunotherapeutics Announces Positive Top-Line Results

Ipsen

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

AB Science SA

FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer...

Nanobiotix

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update